Published on 11th October 2012
GlaxoSmithKline plans to open up much of its drug research in an apparent effort to deflect criticism that important information gathered in clinical trials often does not see the light of day. The move, a first for a major pharmaceutical company, is scheduled to be announced on Thursday by its chief executive, Andrew Witty, in London. The New York Times